Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
86 studies found for:    Ox40
Show Display Options
Rank Status Study
1 Recruiting Stereotactic Body Radiation and Monoclonal Antibody to OX40 in Breast Cancer Patients With Metastatic Lesions
Conditions: Metastatic Breast Cancer;   Lung Metastases;   Liver Metastases
Intervention: Biological: anti-OX40 antibody
2 Unknown  Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
Condition: Advanced Cancer.
Interventions: Drug: Cohort 1 anti-OX40;   Drug: Cohort 2 anti-OX40;   Drug: Cohort 3 anti-OX40;   Biological: Tetanus Day 29;   Biological: Tetanus Day 1;   Biological: KLH Day 1;   Biological: KLH Day 29
3 Withdrawn Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Anti-OX40;   Drug: Ipilimumab
4 Completed A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
Condition: Asthma
Interventions: Drug: huMAb OX40L;   Drug: placebo
5 Recruiting Anti-OX40 Antibody in Head and Neck Cancer Patients
Condition: Head and Neck Cancer
Interventions: Drug: Anti-OX40 antibody administration;   Procedure: Surgical Resection
6 Recruiting Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Conditions: Metastatic Prostate Cancer;   Cancer of the Prostate;   Prostate Cancer
Interventions: Drug: Anti-OX40;   Radiation: Radiation;   Drug: Cyclophosphamide
7 Terminated OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
Condition: Cancer
Interventions: Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy
8 Withdrawn Study of Immune Responses in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Biological: anti-OX40
9 Unknown  Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.
Condition: Critical Ill Patients in SICU
Intervention: Drug: Omegaven 10%
10 Recruiting A Phase 1 Study of MEDI6383 in Adult Subjects With Select Advanced Solid Tumors
Condition: Recurrent or Metastatic Solid Tumors
Intervention: Biological: MEDI6383
11 Recruiting A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Conditions: Advanced Solid Tumors;   Aggressive B-cell Lymphomas
Interventions: Biological: MEDI6469/tremelimumab;   Biological: MEDI6469/MEDI4736;   Biological: MEDI6469/rituximab;   Biological: MEDI6469
12 Recruiting A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Solid Tumors
Condition: Solid Tumors
Intervention: Biological: MEDI0562
13 Recruiting A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With Non-neuroblastoma, GD2+ Solid Tumors
Conditions: Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Melanoma
Interventions: Biological: Anti-GD2-CAR engineered T cells;   Drug: AP1903;   Drug: Cyclophosphamide
14 Recruiting 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
Condition: Neuroblastoma
Interventions: Genetic: iC9-GD2 T Cell Lymphocytes-frozen cells;   Genetic: iC9-GD2 T Cell Lymphocytes-fresh cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
15 Completed Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy
Condition: Glomerulonephritis, IGA
Intervention: Procedure: gene transcription and cytometry
16 Recruiting iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma/VEGAS
Condition: Sarcomas
Interventions: Genetic: GD2 T cells;   Biological: VZV vaccine
17 Completed Assessing the Effects of Omega-3 Supplementation on Serum HSP27, HSP70, YKL40, BMP-4 Levels in Male Patient With CAD
Condition: Cardiovascular Disease
Interventions: Dietary Supplement: Omega-3;   Dietary Supplement: Placebo
18 Completed Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: 40K PEG-rFIX
19 Completed
Has Results
Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing
Condition: Rheumatoid Arthritis
Interventions: Drug: adalimumab;   Drug: Placebo
20 Completed
Has Results
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine
Condition: Meningococcal Disease
Interventions: Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine.;   Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years